Projected 2018 sales: $1.283 billion
2012 sales: N/A
It's not yet approved, but hopes are certainly high for ibrutinib, the Bruton's tyrosine kinase (BTK) inhibitor bursting with blockbuster potential. The compound, which could be revolutionary in treating B-cell cancers like chronic lymphocytic leukemia and mantle cell lymphoma, has shown impressive results and response rates in clinical trials up through its Phase III studies. Johnson & Johnson's ($JNJ) Janssen unit delivered the new drug application to the FDA this month, setting the stage for an early approval.
The FDA has already shown its interest in the compound, granting it the coveted "Breakthrough Therapy" label not one but three times in separate groups of cancer patients. With the agency's go-ahead, ibrutinib could be cleared for U.S. sales before the calendar year is out.
Co-developer Pharmacyclics ($PCYC) is already reaping the benefits. The compound's prospects have driven the market value of the company to more than $5 billion, the highest among clinical-stage oncology companies.
J&J files FDA app for fast-moving cancer candidate ibrutinib
Pharmacyclics bounces higher as J&J wins third 'breakthrough' cancer drug coup
J&J, Pharmacyclics score 'breakthrough' coup with blockbuster hopeful ibrutinib